Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9
04 juin 2018 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, June 04, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announced today that results from a Phase 2b/3 trial with PRO 140 (humanized CCR5 monoclonal antibody) in heavily...
Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials
24 mai 2018 17h00 HE
|
CytoDyn Inc.
Data Provide Support for PRO 140 as long-acting, HIV-1 maintenance therapy VANCOUVER, Washington, May 24, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announces that results from its CD01...
CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018
11 avr. 2018 16h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 11, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders
29 mars 2018 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 29, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) announces the formation of a Scientific Advisory Board to advise on the development of PRO 140 in certain...
CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD
14 mars 2018 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 14, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection
20 févr. 2018 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Feb. 20, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY) reports the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO...
Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint
07 déc. 2017 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV)...
CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation
14 nov. 2017 06h00 HE
|
CytoDyn Inc.
PRO 140 Currently in Phase 2 Clinical Trial in Leukemia Patients Receiving Bone Marrow Transplants Preclinical Proof-of-Concept Published in Biology of Blood and Marrow Transplantation VANCOUVER,...
CytoDyn Announces Investment Community Conference Call for October 19, 2017
17 oct. 2017 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Oct. 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency...
CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA
13 oct. 2017 06h00 HE
|
CytoDyn Inc.
Interim efficacy analysis of primary endpoint to be conducted in coming weeks Company to hold investment community conference call on October 19 VANCOUVER, Washington, Oct. 13, 2017 (GLOBE...